Cafelkibart’s entry into phase 3 is of note to Coherus.
ApexOnco Front Page
Recent articles
The company is starting four new pivotal trials this year.
GEN1286 looks dead, though MCLA-129 continues for now.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
And the company says it won’t need to carry out another trial.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
